Soc. Generale Knock-Out SNW/ DE000CL9BX09 /
5/21/2024 8:26:36 AM | Chg.-0.03 | Bid8:28:01 AM | Ask8:28:01 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.52EUR | -1.94% | 1.53 Bid Size: 2,000 |
1.57 Ask Size: 2,000 |
SANOFI SA INHABER ... | 74.3372 - | 12/31/2078 | Call |
GlobeNewswire
7:30 AM
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
5/13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
5/8
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/7
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
5/2
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
4/25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance